Pharmacodynamic analysis of steroid 5α-reductase inhibitory actions of Z-350 in rat prostate

European Journal of Pharmacology

Volumn 426, Issue 1-2, 2001, Pages 105-111

  Furuta, Shigeru ^a   Fukuda, Youich ^a   Sugimoto, Tohru ^a   Miyahara, Haruka ^a   Kamada, Emiko ^a   Sano, Hiroshi ^a   Fukuta, Yoshihisa ^a   Takei, Mineo ^a   Kurimoto, Tadashi ^a  

^a ZERIA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Reductase; Phamacodynamics; Plasma concentration; Prostate concentration; Z 350

Indexed keywords

4 [3 [4 [1 (4 METHYLPHENYL) 3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPOXY]BENZOYL]INDOL 1 YL] BUTYRIC ACID HYDROCHLORIDE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; Z 350;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; RAT;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; ENZYME INHIBITORS; INDOLES; MALE; METABOLIC CLEARANCE RATE; PIPERAZINES; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS;

EID: 0035943335     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01208-0     Document Type: Article

References (19)

1. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia
2. Pharmacological properties of Z-350, which processes α1-adenoceptor antagonistic and steroid 5α-reductase inhibitory actions; (1) in vitro studies
3. Z-350, a new chimera compound possessing α1-adenoceptor antagonistic and steroid 5α-reductase inhibitory actions
4. Hormonal effects of Z-350, possessing 5α-reductase inhibitory and α1-adenoceptor antagonistic in the rat
5. Pharmacological properties of Z-350, which processes α1-adenoceptor antagonistic and steroid 5α-reductase inhibitory actions; (2) in vivo studies
6. Z-350, A novel compound with α1-adenoceptor antagonistic and steroid 5α-reductase inhibitory actions: Pharmacological properties in vivo
7. Effect of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers
8. The pharmacodynamic and pharmacokinetic interaction of pentobarbital and chlorpromazine in rats
9. FK-143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (1) In vitro effects on human and animal prostatic enzymes
10. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models
11. Comparative study of 1.5-hour and 48-hour homologous passive cutaneous anaphylaxis in the mouse ear
12. Binding of drug to tissues
13. Effect of MK-906, a specific 5α-reductase inhibitor, on the serum androgens and androgen conjugates in normal men
14. Synthesis and pharmacological activities of dual acting agent having α 1-adenoceptor antagonistic action and 5α-reductase inhibition
15. Measurement of protein using bicinchoninic acid
16. Kinetic analysis of rat steroid 5α-reductase activity in prostate and epididymis homogenates at neutral pH: Evidence for type I activity in epididymis
17. Alpha1-adenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonists
18. A nonlinear least squares program based on differential equations, MULTI(RUNGE), for microcomputers
19. A pharmacokinetic analysis program (MULTI) for microcomputer